New agents: Great expectations not realized

Best Practice and Research: Clinical Haematology

Volumn 26, Issue 3, 2013, Pages 269-274

  Lancet, Jeffrey E ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

AC220; acute myeloid leukemia AML; clofarabine; CPX 351; FLAM; flavopiridol; FLT3 inhibitor; gemtuzumab; laromustine; lestaurtinib; lintuzumab; midostaurin; quizartinib; sapacitabine; tipifarnib

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMONAFIDE; ANTIBIOTIC AGENT; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; BORTEZOMIB; CLOFARABINE; CPX 351; CYTARABINE; DAUNORUBICIN; FLAVOPIRIDOL; GEMTUZUMAB OZOGAMICIN; LAROMUSTINE; LENALIDOMIDE; LESTAURTINIB; LINTUZUMAB; MIDOSTAURIN; MITOXANTRONE; QUIZARTINIB; SAPACITABINE; SORAFENIB; TIPIFARNIB; TROXACITABINE; UNCLASSIFIED DRUG; VALSPODAR; VORINOSTAT; VOSAROXIN; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG TREATMENT FAILURE; FALSE POSITIVE RESULT; HUMAN; LOW DRUG DOSE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

AC220; ACUTE MYELOID LEUKEMIA, AML; CLOFARABINE; CPX-351; FLAM; FLAVOPIRIDOL; FLT3 INHIBITOR; GEMTUZUMAB; LAROMUSTINE; LESTAURTINIB; LINTUZUMAB; MIDOSTAURIN; QUIZARTINIB; SAPACITABINE; TIPIFARNIB;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; BENZOTHIAZOLES; CYTOSINE; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOID, ACUTE; NAPHTHYRIDINES; PHENYLUREA COMPOUNDS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; STAUROSPORINE; SURVIVAL ANALYSIS; THIAZOLES; TREATMENT FAILURE;

EID: 84889647348     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2013.10.007     Document Type: Review

References (20)

1. A.K. Burnett, N.H. Russell, and R.K. Hills Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia J Clin Oncol 30 2012 3924 3931
2. S. Castaigne, C. Pautas, and C. Terre Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study Lancet 379 2012 1508 1516
3. R.B. Walter, F.R. Appelbaum, and M.S. Tallman Shortcomings in the clinical evaluation of new drugs: Acute myeloid leukemia as paradigm Blood 116 2010 2420 2428
4. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10
5. G.J. Schiller, S.M. O'Brien, and A. Pigneux Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia J Clin Oncol 28 2010 815 821
6. H.M. Kantarjian, H.P. Erba, and D. Claxton Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors J Clin Oncol 28 2010 549 555
7. J.L. Harousseau, G. Martinelli, and W.W. Jedrzejczak A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older Blood 114 2009 1166 1173
8. M.A. Sekeres, J.E. Lancet, and B.L. Wood Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia Haematologica 98 2013 119 128
9. J.E. Lancet, I. Gojo, and J. Gotlib A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia Blood 109 2007 1387 1394
10. J.P. Patel, M. Gonen, and M.E. Figueroa Prognostic relevance of integrated genetic profiling in acute myeloid leukemia N Engl J Med 366 2012 1079 1089
11. M. Raponi, J.E. Lancet, and H. Fan A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia Blood 111 2008 2589 2596
12. S. Faderl, M. Wetzler, and D. Rizzieri Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: Results from the CLASSIC I Trial J Clin Oncol 30 2012 2492 2499
13. M. Jan, and R. Majeti Clonal evolution of acute leukemia genomes Oncogene 32 2013 135 140
14. P. Tardi, S. Johnstone, and N. Harasym In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy Leuk Res 33 2009 129 139
15. E.J. Feldman, J.E. Lancet, and J.E. Kolitz First-in-man study of CPX-351: A liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia J Clin Oncol 29 2011 979 985
16. J.E. Lancet, J.E. Cortes, and D.E. Hogge Phase 2b randomized study of CPX-351 vs cytarabine (CYT)+daunorubicin (DNR) (7+3 regimen) in newly diagnosed AML patients aged 60-75 Blood (ASH Annual Meeting Abstracts) 116 2010 abstr 655
17. J.F. Zeidner, J.M. Gerber, and A. Blackford Randomized phase 2 trial of timed-sequential therapy (TST) with flavopiridol (Alvocidib), Ara-C and mitoxantrone (FLAM) versus "7+3" for adults ages 70 years and under with newly diagnosed acute myeloid leukemia (AML) Blood (ASH Annual Meeting Abstracts) 120 2012 abstr 47
18. M. Levis, F. Ravandi, and E.S. Wang Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse Blood 117 2011 3294 3301
19. J.E. Cortes, A.E. Perl, and H. Dombret Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients >60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia Blood (ASH Annual Meeting Abstracts) 120 2012 abstr 48
20. M.J. Levis, A.E. Perl, and H. Dombret Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation Blood (ASH Annual Meeting Abstracts) 120 2012 abstr 673